COMPOUND DEEP DIVES
Pinealon is a short-chain peptide bioregulator consisting of three amino acids — glutamic acid, aspartic acid, and arginine (Glu-Asp-Arg, or EDR) — first isolated and characterized by researchers at the St. Petersburg Institute of Bioregulation and Gerontology. Preclinical investigations suggest that this tripeptide exerts targeted regulatory activity in neuronal tissue, with research interest concentrated on its potential role in cognitive aging models, retinal cell protection, and gene expression modulation via epigenetic pathways. This article surveys the current body of published preclinical evidence on the Pinealon neuropeptide.
Pinealon belongs to a class of compounds known as peptide bioregulators — short amino acid sequences theorized to serve as tissue-specific gene expression modulators. The peptide’s sequence, Glu-Asp-Arg, was derived through isolation work conducted at the St. Petersburg Institute of Bioregulation and Gerontology by Professor Vladimir Khavinson and colleagues. Published findings from Khavinson VKh et al. in Bulletin of Experimental Biology and Medicine describe the pineal-targeting characteristics of EDR and its apparent tropism for neural and retinal tissue in animal models.
The rationale for studying the EDR sequence stems from broader research into the role of the pineal gland in circadian regulation and neurological homeostasis. Because the pineal gland produces melatonin and plays a documented role in aging biology, researchers have hypothesized that peptides with affinity for pineal-associated tissue may carry implications for age-associated neurological decline — a question now being explored actively in preclinical settings.
For related background on peptide bioregulators being studied for cognitive endpoints, see our overview of Selank and Semax in nootropic peptide research.
One of the more compelling areas of Pinealon research concerns its putative epigenetic activity. Studies from the Khavinson laboratory have reported that short peptides — including the EDR sequence — appear capable of binding directly to double-stranded DNA and histone proteins, influencing chromatin conformation and downstream gene expression in cell culture and animal models. This mechanism is referred to as peptide-chromatin interaction and has been described in peer-reviewed publications in Journal of Peptide Science and associated biogerontology literature.
Specifically, preclinical data indicate that the Pinealon neuropeptide may upregulate expression of anti-apoptotic and neuroprotective genes — including those encoding antioxidant enzymes — through histone acetylation-related pathways. In aged rat models, EDR administration was associated with measurable changes in gene expression profiles within brain tissue, though mechanistic confirmation in higher-order species remains an area of active investigation.
The epigenetic framing is significant: if short peptides can modulate gene expression without altering the underlying DNA sequence, they represent a distinct pharmacological class with a wide theoretical application space in aging and neurodegeneration research. Researchers note, however, that translating epigenetic observations from cell culture to intact animal models — and interpreting those results for human relevance — requires additional controlled study.
The preponderance of Pinealon research has focused on two parallel applications: cognitive aging models and retinal cell protection. In aged animal models, administration of the EDR tripeptide has been associated with improvements in behavioral markers of spatial memory and learning performance compared to untreated controls. Khavinson VKh and colleagues reported in Bull Exp Biol Med that EDR-treated aged rodents showed improvements in maze navigation tasks, with corresponding histological findings suggestive of reduced neuronal apoptosis in hippocampal tissue.
Retinal research represents a parallel line of inquiry. The retina is central nervous system tissue, and preclinical models of retinal degeneration — including those induced by oxidative stress and ischemia — have been used to test the EDR peptide’s cytoprotective potential. Published animal studies have reported reductions in retinal ganglion cell loss and preservation of photoreceptor density in EDR-treated groups relative to controls. These findings have prompted interest in Pinealon as a candidate compound for future studies targeting age-associated retinal conditions, though no human clinical trials have been registered or completed as of the publication of this article.
Additional context on related peptide aging research can be found in our article on Epithalon, telomeres, and anti-aging research models.
The following table provides a summary comparison of Pinealon alongside three other peptides frequently studied in overlapping neurological and cognitive research contexts. All data refer exclusively to preclinical and animal model findings.
| Compound | Sequence / Class | Primary Research Focus | Proposed Mechanism | Key Research Source |
|---|---|---|---|---|
| Pinealon (EDR) | Tripeptide (Glu-Asp-Arg) | Cognitive aging, retinal neuroprotection | Epigenetic gene regulation, anti-apoptotic pathways | Khavinson VKh et al., Bull Exp Biol Med |
| Selank | Heptapeptide (tuftsin analogue) | Anxiety models, memory consolidation | GABAergic modulation, BDNF expression | Semenova TP et al., Bull Exp Biol Med |
| Semax | ACTH(4-7) analogue heptapeptide | Cognitive performance, neuroprotection post-ischemia | NGF/BDNF upregulation, ACTH receptor interaction | Grivennikov IA et al., Mol Biol (Mosk) |
| Epithalon | Tetrapeptide (Ala-Glu-Asp-Gly) | Telomere biology, longevity markers | Telomerase activation, pineal-melatonin axis | Khavinson VKh et al., Neuro Endocrinol Lett |
The retina is an extension of the central nervous system — a sheet of photoreceptive neural tissue that shares many of the same vulnerability profiles as brain tissue under conditions of oxidative stress, ischemia, and age-related degeneration. For this reason, preclinical retinal models have become an important testing ground for neuroprotective compounds, including the EDR tripeptide Pinealon. Research from the Khavinson laboratory has produced a distinct sub-literature examining Pinealon’s activity in retinal and visual system contexts, with findings that extend the neuroprotective narrative beyond cognitive endpoints.
In retinal ganglion cell (RGC) protection studies using rodent models, administration of the EDR peptide was associated with reduced cell death in the ganglion cell layer following experimentally induced ischemia-reperfusion injury. Retinal ganglion cells are particularly susceptible to apoptotic cascades triggered by oxidative stress and excitotoxic insult — conditions that replicate, at least partially, the cellular environment observed in age-associated retinal diseases. In treated animal groups, histological analysis showed a measurable preservation of RGC density relative to untreated controls, consistent with an anti-apoptotic effect at the cellular level. These findings were reported in studies indexed in Russian-language biomedical literature as well as English-language abstracts available through PubMed-affiliated databases.
Oxidative stress models have been a particularly productive framework for evaluating Pinealon’s retinal effects. In cell culture experiments using isolated retinal preparations exposed to hydrogen peroxide and other oxidative insults, pretreatment with EDR peptide was associated with attenuation of reactive oxygen species (ROS) accumulation and improved cell viability markers compared to vehicle-treated controls. The proposed mechanism aligns with Pinealon’s broader epigenetic activity: upregulation of antioxidant-encoding genes — including those related to superoxide dismutase and catalase expression — via peptide-chromatin interaction, reducing the transcriptional deficit that typically accompanies oxidative challenge in aged retinal tissue.
From an aging-biology perspective, the visual system undergoes well-documented structural and functional decline with advancing age. Photoreceptor density decreases, the retinal pigment epithelium accumulates lipofuscin deposits, and RGC axonal transport efficiency diminishes — all changes observable in rodent aging models. Khavinson and colleagues used this natural aging trajectory as a backdrop for evaluating whether peptide bioregulator intervention could slow or partially reverse these cellular hallmarks. Published data from aged rat cohorts treated with EDR showed preservation of retinal layer thickness and more favorable RGC survival rates compared to age-matched controls receiving vehicle only, supporting the hypothesis that the peptide may exert a tissue-protective effect relevant to visual system aging.
It should be emphasized that all findings summarized here originate from animal and cell-based preclinical models. No human clinical trials investigating Pinealon’s effects on retinal function or visual system health have been registered or published. The translational relevance of these findings to human retinal disease remains entirely speculative and constitutes a legitimate area for future controlled investigation.
Pinealon is the research name for the tripeptide Glu-Asp-Arg (EDR), where each letter represents the single-letter amino acid code: E for glutamic acid, D for aspartic acid, and R for arginine. It was developed and characterized through preclinical research at the St. Petersburg Institute of Bioregulation and Gerontology.
Preclinical research on the Pinealon neuropeptide has primarily examined its effects in cognitive aging animal models, retinal cell protection studies, and epigenetic gene regulation investigations. Studies have been published in peer-reviewed journals including Bulletin of Experimental Biology and Medicine and Journal of Peptide Science. All reported findings are from laboratory and animal model contexts.
The foundational research on Pinealon and related peptide bioregulators was conducted by Professor Vladimir Khavinson (Khavinson VKh) and research teams at the St. Petersburg Institute of Bioregulation and Gerontology, one of Russia’s leading institutions in biogerontology and peptide biology. Their published work spans multiple decades and dozens of peer-reviewed publications.
While Semax and Selank appear to act primarily through neurotrophin pathways (BDNF, NGF) and neurotransmitter receptor interactions respectively, research suggests Pinealon’s neuroprotective effects may be more closely linked to direct DNA/histone interaction and epigenetic gene regulation. These are distinct mechanistic hypotheses, each supported by separate bodies of preclinical evidence, and they are not mutually exclusive in terms of future research applications.
No. Pinealon is available exclusively as a research compound for use in certified laboratory settings. It is not approved for human consumption by any regulatory authority, has not completed human clinical trials, and is not intended for any therapeutic, diagnostic, or personal use application. All research cited in this article is conducted in preclinical animal or cell culture models.
Both Pinealon (EDR) and Epithalon (AEDG) are short peptide bioregulators developed by the Khavinson research group and have been studied in aging contexts. Epithalon research has concentrated on telomere elongation and the pineal-melatonin axis, while Pinealon research has focused more specifically on neuronal and retinal tissue protection and cognitive aging markers in animal models. Both remain in the preclinical research phase.
View Pinealon research compound →
Each compound available on biohacker.team is verified by our specialist research team through independent third-party HPLC authentication, with batch-level certificates of analysis published openly. Our experts cross-reference purity data against established preclinical literature before each batch is listed.
This article is for informational and educational purposes only. All compounds discussed are intended strictly for laboratory and scientific research use. Not for human consumption. Not for sale to the public.